Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provention Bio Inc.

www.proventionbio.com

Latest From Provention Bio Inc.

Lilly, Galapagos Put Some Trials On Hold Due To Coronavirus Concerns

Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.

Clinical Trials Coronavirus COVID-19

Syncona Biotechs Face Up To Trial Delays Over COVID-19

Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.

Coronavirus COVID-19 Clinical Trials

Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist

Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.

Clinical Trials Coronavirus COVID-19

As Sanofi Exits Diabetes R&D, Meaning Of ‘Diabetes R&D’ Blurs

Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.

Metabolic Disorders Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Provention Bio Inc.
  • Senior Management
  • Ashleigh Palmer, CEO
    Andrew Drechsler, CFO
    Francisco Leon, MD, PhD, CSO
    Eleanor Ramos, MD, CMO & COO
  • Contact Info
  • Provention Bio Inc.
    Phone: (908) 336-0360
    P.O. Box 666 Oldwick, NJ 08858
    USA
UsernamePublicRestriction

Register